Market capitalization | HKD60.70b |
Enterprise Value | HKD66.91b |
P/E (TTM) P/E ratio | 22.35 |
EV/FCF (TTM) EV/FCF | 9.19 |
EV/Sales (TTM) EV/Sales | 2.31 |
P/S ratio (TTM) P/S ratio | 2.09 |
P/B ratio (TTM) P/B ratio | 1.72 |
Dividend yield | 1.82% |
Last dividend (FY23) | HKD0.06 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
28 Analysts have issued a Sino Biopharmaceutical forecast:
28 Analysts have issued a Sino Biopharmaceutical forecast:
Jun '24 |
+/-
%
|
||
Revenue | 29,002 29,002 |
11%
11%
|
|
Gross Profit | 24,046 24,046 |
6%
6%
|
|
EBITDA | 7,613 7,613 |
9%
9%
|
EBIT (Operating Income) EBIT | 6,668 6,668 |
4%
4%
|
Net Profit | 2,723 2,723 |
28%
28%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.
Head office | Cayman Islands |
CEO | S Tse |
Employees | 25,806 |
Founded | 2000 |
Website | www.sinobiopharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.